This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. Cemiplimab is the first FDA approval of a medication specifically for advanced cutaneous squamous cell carcinoma (CSCC).
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:kegg |
|
| dbo:medlinePlus |
|
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chemspiderid |
|
| dbp:dailymedid |
|
| dbp:drugbank |
|
| dbp:eliminationHalfLife |
|
| dbp:h |
|
| dbp:kegg |
|
| dbp:legalAu |
|
| dbp:legalCa |
|
| dbp:legalEu |
|
| dbp:legalStatus |
|
| dbp:legalUs |
|
| dbp:mabType |
|
| dbp:medlineplus |
|
| dbp:n |
|
| dbp:o |
|
| dbp:pregnancyAu |
|
| dbp:pronounce |
|
| dbp:routesOfAdministration | |
| dbp:s |
|
| dbp:source |
|
| dbp:synonyms |
|
| dbp:target | |
| dbp:tradename |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of |
|
| is foaf:primaryTopic of |